Search clinical trials for: Recombinant humanized anti-PD-1 monoclonal antibody for injection

Total 1075 results

Lee's Pharmaceutical Limited

Recruiting

Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Gastric Cancer | HER2 Overexpressing Gastric Carcinoma

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC

Colorectal Cancer | Multiple Cancer

China
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Australia, Belgium, Chile, Colombia, Czechia, Denmark, Hungary, Israel, Malaysia, New Zealand, Philippines, Poland, Russian Federation, South Africa, Sweden, Thailand
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

Eosinophilic Asthma

United States, Argentina, Brazil, Canada, France, Mexico, Germany, Greece, Korea, Republic of, Peru, Romania, Russian Federation, Slovakia, Taiwan, Ukraine
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors (IUNU-RC)

Non-clear Renal Cell Carcinoma

China
Luye Pharma Group Ltd.

Recruiting

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Bone Metastases From Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers

Healthy
Pfizer

Withdrawn

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer

Poland, United States
HuniLife Biotechnology, Inc.

Recruiting

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001

Idiopathic Pulmonary Fibrosis

Taiwan
Shanghai Zhongshan Hospital

Not yet recruiting

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Non-Small Cell Lung Cancer

China
Cancer Hospital of Guangxi Medical University

Recruiting

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Sintilimab

China
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Nasopharyngeal Carcinoma

China
Sanofi

Completed

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

Paroxysmal Nocturnal Hemoglobinuria

United States
Hunan Cancer Hospital

Recruiting

Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

Chemotherapy Effect | NK/T-cell Lymphoma of Nasal Cavity | Immune Checkpoint Inhibitor | Epigenetic Disorder

China
Henan Cancer Hospital

Recruiting

PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma

Gastric and Esophagogastric Junction Adenocarcinoma

China
Guangzhou Gloria Biosciences Co., Ltd.

Recruiting

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer (CC)

Cervical Cancer

China
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Belgium, Colombia, Hungary, Israel, Poland, Sweden, Argentina, Brazil, Canada, France, Mexico, Netherlands
Sun Yat-sen University

Not yet recruiting

Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL (SPENT)

Extranodal NK/T-cell Lymphoma, Nasal Type

China
CSL Behring

Completed

Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects

Healthy

Australia
Guangzhou Gloria Biosciences Co., Ltd.

Unknown

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Classical Hodgkin's Lymphoma

China
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States, Taiwan, Australia
PDL BioPharma, Inc.

Completed

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Jonsson Comprehensive Cancer Center
Genentech, Inc.

Completed

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Glioblastoma | Gliosarcoma | Giant Cell Glioblastoma

United States
Case Comprehensive Cancer Center

Terminated

Radiosurgery Plus Bevacizumab in Glioblastoma

Glioblastoma | Brain Tumor | Gliosarcoma

United States
Zhejiang University

Recruiting

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Fudan University

Active, not recruiting

Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer

Thyroid Cancer

China
Beijing Friendship Hospital

Completed

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Advanced Solid Tumor

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Actinium Pharmaceuticals

Completed

Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies

Leukemia | Myelodysplastic Syndrome

United States
AVEO Pharmaceuticals, Inc.
Bristol-Myers Squibb

Completed

Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC

Carcinoma, Renal Cell

France
Sinocelltech Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC

Metastatic Colorectal Cancer

China
Chinese PLA General Hospital
Wuxi Sinotide New Drug Discovery Institutes

Recruiting

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Qilu Pharmaceutical Co., Ltd.

Terminated

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic
CSL Behring

Completed

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

Hidradenitis Suppurativa | Palmoplantar Pustulosis

Denmark, Australia, Germany
Shanghai Celfuture Biotech Co., Ltd.

Not yet recruiting

A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Colorectal Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers

Metastatic Cancer | Advanced Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Locally Advanced Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Oncocytic Carcinoma

United States
Changhai Hospital

Recruiting

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Advanced Cancer | Pancreatic Ductal Adenocarcinoma

China
Jinling Hospital, China

Recruiting

Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC

Neoplasms | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Carcinoma | Antineoplastic Agents | Male Urogenital Diseases | Female Urogenital Diseases | Immune Checkpoint Inhibitors | Urogenital Diseases

China
Biogen

Completed

BIIB033 In Acute Optic Neuritis (AON)

Acute Optic Neuritis

Sweden, Australia, Italy, Spain, United Kingdom, Germany, Belgium, Denmark, Hungary, Czech Republic, Canada
Zhejiang Cancer Hospital

Completed

Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Eosinophilic Asthma

United States
Shanghai Henlius Biotech

Recruiting

Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Age Related Macular Degeneration

China
Genor Biopharma Co., Ltd.

Unknown

Clinical Trial in Chinese Healthy Volunteers of GB222

Non-small Cell Lung Cancer

China
United BioPharma

Not yet recruiting

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults

HIV-1-infection
Merck KGaA, Darmstadt, Germany

Terminated

TRUST Study: Raptiva ® in Hand & Foot Psoriasis (TRUST)

Chronic Plaque Psoriasis

Austria
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

Head and Neck Cancer

China
Zhejiang University
Zcapsule Pharmaceuticals (Shaoxing) Co., Ltd

Recruiting

The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1

Ovarian Cancer | Bladder Cancer | Small-cell Lung Cancer | Liver Cancer | Esophagus Cancer

China
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States

Search clinical trials for: Recombinant humanized anti-PD-1 monoclonal antibody for injection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations